Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) — Stella
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(9 sites)
United States
University of California San Diego, San Diego, California
Dana-Farber Cancer Institute, Boston, Massachusetts
Washington University in St. Louis, St Louis, Missouri
X Cancer Omaha / Urology Cancer Center, Omaha, Nebraska
Laura & Isaac Perlmutter Cancer Center, New York, New York
Memorial Sloan Kettering Cancer Center, New York, New York
New York Presbyterian/Weill Cornell Medical Center, New York, New York
Duke University Medical Center, Durham, North Carolina